HETEROGENEITY OF THE EFFECT OF COMBINED FRACTIONATED RADIOTHERAPY AND EGFR/HER2 TYROSINE KINASE INHIBITION

被引：0

作者：

Gurtner, K. ^{[1
,2
]}

Schuetze, C. ^{[1
,2
]}

Soica, F. ^{[3
]}

Baumann, M. ^{[1
,2
]}

Krause, M. ^{[1
,2
]}

机构：

[1] Tech Univ, Dept Radiat Oncol, OncoRay Ctr Radiat Res Oncol, Fac Med, Dresden, Germany

[2] Tech Univ, Dept Radiat Oncol, OncoRay Ctr Radiat Res Oncol, Univ Hosp Carl Gustav Carus, Dresden, Germany

[3] Boehringer Ingelheim Austria, Vienna, Austria

来源：

RADIOTHERAPY AND ONCOLOGY | 2008年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

128

引用

页码：S42 / S43

页数：2

共 50 条

[41] Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma [J].

Li, Jianhong ;

Jackson, Cynthia L. ;

Yang, Dongfang ;

Noble, Lelia ;

Wheeler, Michael ;

MacKenzie, Dolores ;

Adegun, Temitope ;

Amin, Ali .

TARGETED ONCOLOGY, 2015, 10 (03) :355-363

[42] Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer [J].

Marin, Arnaldo ;

Al Mamun, Abdullah ;

Patel, Hima ;

Akamatsu, Hiroaki ;

Ye, Dan ;

Sudhan, Dhivya R. ;

Eli, Lisa ;

Marcelain, Katherine ;

Brown, Benjamin P. ;

Meiler, Jens ;

Arteaga, Carlos L. ;

Hanker, Ariella B. .

CANCER RESEARCH, 2023, 83 (18) :3145-3158

[43] Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors [J].

Chandrika, Bhavya Balan ;

Steephan, Mathew ;

Kumar, T. R. Santhosh ;

Sabu, A. ;

Haridas, M. .

LIFE SCIENCES, 2016, 160 :47-56

[44] Tucatinib (HER2 Tyrosine Kinase Inhibitor)-Induced Liver Injury [J].

Feng, Yan ;

Gonzalez, Ivan ;

Zhang, Dongwei .

LABORATORY INVESTIGATION, 2025, 105 (03)

[45] AXL signaling promotes adaptive resistance to HER2 tyrosine kinase inhibitors in HER2 aberrant tumor cells [J].

Ishida, Masaki ;

Yamada, Tadaaki ;

Katayama, Yuki ;

Yasumoto, Kazuo ;

Takayama, Koichi .

CANCER RESEARCH, 2025, 85 (08)

[46] Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer [J].

Lu Yang ;

Arup Bhattacharya ;

Yun Li ;

Sandra Sexton ;

Xiang Ling ;

Fengzhi Li ;

Yuesheng Zhang .

Journal of Experimental & Clinical Cancer Research, 41

[47] Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer [J].

Yang, Lu ;

Bhattacharya, Arup ;

Li, Yun ;

Sexton, Sandra ;

Ling, Xiang ;

Li, Fengzhi ;

Zhang, Yuesheng .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)

[48] HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer [J].

Takezawa, Ken ;

Melnick, Mary Ann ;

Riely, Greg ;

Kris, Mark ;

Miller, Vincent ;

Ladanyi, Marc ;

Politi, Katerina ;

Pao, William ;

Pirazzoli, Valentina ;

Song, Xiaoling ;

Arcila, Maria ;

De Stanchina, Elisa ;

Ohashi, Kadoaki ;

Janjigian, Yelena ;

Spitzler, Paula ;

Nebhan, Caroline .

CLINICAL CANCER RESEARCH, 2012, 18 (10)

[49] The combination of the HER2 antibody trastuzumab, the EGFR tyrosine kinase inhibitor gefitinib, and docetaxel as first-line therapy in patients with HER2 overexpressing stage IV breast carcinoma [J].

Somlo, G. ;

Koczywas, M. ;

Luu, T. ;

McNamara, M. ;

Bedell, V. ;

Slovak, M. L. ;

Wilczynski, S. ;

Morgan, R. ;

Russell, C. ;

Frankel, P. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

[50] Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase [J].

Garrett, Joan T. ;

Olivares, Maria Graciela ;

Rinehart, Cammie ;

Granja-Ingram, Nara D. ;

Sanchez, Violeta ;

Chakrabarty, Anindita ;

Dave, Bhuvanesh ;

Cook, Rebecca S. ;

Pao, William ;

McKinely, Eliot ;

Manning, H. C. ;

Chang, Jenny ;

Arteaga, Carlos L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (12) :5021-5026

← 1 2 3 4 5 →